… in idiopathic pulmonary fibrosis (IPF), where they hold the potential to elucidate underlying
disease mechanisms, accelerated drug development, … The successful development of useful …

… strides are being made toward the development of useful therapies. Improved … drug
development. In addition, refinement in the classification of interstitial lung disease and development …

… Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary interstitial inflammatory
disease of … Nintedanib and pirfenidone are the only two known drugs which are conditionally …

… the latest research as well as knowledge gaps in idiopathic pulmonary fibrosis (IPF). …
These comparative studies may facilitate drug development, particularly of agents that may be …

… Finally, we analyze the mechanism of action, the efficacy and the current status of
different drugs developed to inhibit the oxidative stress as anti-fibrotic therapy in IPF. …

… of pulmonary fibrosis, and includes a more detailed discussion of the potential points of
therapeutic attack in pulmonary fibrosis. … of pulmonary fibrosis, and which have been developed …

… due to limited availability of effective drug therapies, a lack of … approach to the development
of novel anti-fibrotic agents. … the major issues holding back drug development in IPF. The …

… Drugs targeting several of these are under investigation in various stages of clinical
development. Here, we provide a brief overview of the drugs that are currently approved and others …

… ) is a cytokine implicated in the development of fibrosis by contributing to myofibroblast …
higher preventing pharmaceutical companies from investing and developing new drugs for IPF. In …

… Drug discovery programs in IPF seek to inhibit inappropriate … Schematic diagram of concepts
in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and potential targets to modulate …